Liquidia Technologies, Inc.
Clinical trials sponsored by Liquidia Technologies, Inc., explained in plain language.
-
New inhaled powder shows promise for Lung-Related high blood pressure
Disease control OngoingThis study is testing the safety of an inhaled dry powder drug called LIQ861 (treprostinil) in 80 adults with pulmonary hypertension (high blood pressure in the lungs) linked to lung disease or other causes. Participants receive the drug through an inhaler, and researchers monito…
Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated May 26, 2026 11:52 UTC
-
New inhaled therapy aims to ease rare lung pressure condition
Disease control OngoingThis study tests the safety of an inhaled medication called L606 for people with high blood pressure in the lungs (pulmonary arterial hypertension or pulmonary hypertension from lung disease). About 28 adults will switch to or start L606 and be monitored for side effects over wee…
Phase: PHASE3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated May 26, 2026 11:51 UTC